Sustainability at Biocon
Generics: Q4FY22 and full year FY22 Update
KEY Q4 HIGHLIGHTS
Q4 FY22
Robust sequential and YoY growth in Q4 driven by API sales ramp
up, new launches in the US & normalization of operations
Posaconazole and Dorzolamide, launched in the US;
1st MoW market launch in Mexico; 1st approval in Singapore & in the
UAE
Successful site inspection by Health Canada at Bengaluru API
manufacturing unit
Biocon 1
Q4 FY21
Revenue
*717Cr
*570Cr
+26%
Profit Before Tax (PBT)
116Cr
*73Cr
+59%
16% of revenue
13% of revenue
FY22
FY 21
Revenue
*2,363Cr
On track to qualify & validate Vizag API facility in FY23; to commence
new manufacturing expansion projects in Hyderabad & Bengaluru
*2,341Cr
Profit Before Tax (PBT)
Diversified renewable power consumption to solar & wind energy
*261Cr
11% of revenue
*291 Cr
12% of revenue
12View entire presentation